HIQA on Gene Expression Profiling Tests for Breast Cancer

By Staff Writer

February 21, 2023

Introduction:

There is an ongoing and unrelenting effort to find better treatments for breast cancer, which is a major health concern worldwide. One promising development in this respect is the use of gene expression profiling (GEP) tests. These tests, performed on tumour samples from early-stage breast cancer patients, can help determine the potential benefits of chemotherapy post-surgery.

Gene Expression Profiling Tests in Breast Cancer:

The Health Information and Quality Authority (HIQA) recently published a rapid health technology assessment (HTA) on GEP tests for breast cancer. This was at the request of the Health Service Executive’s (HSE) National Cancer Control Programme. These tests are particularly useful for patients with the most common form of breast cancer in Ireland. The tests aim to estimate the likelihood of the disease returning and the potential effectiveness of chemotherapy in preventing recurrence.

The Oncotype DX® Test:

Currently, the HSE covers the cost of one GEP test, known as Oncotype DX®. When it comes to patients whose cancer has migrated to their lymph nodes, this test has demonstrated the most compelling proof of its usefulness. On the other hand, the data that supports its use for patients whose cancer has not progressed to their lymph nodes is very restricted.

The Future of GEP Tests:

Despite the promising results of Oncotype DX®, the costs of other GEP tests are not covered. HIQA’s assessment examined the evidence for all four commercially available tests in Ireland. The aim was to provide advice to the HSE on potential alternatives. The decision to cover the cost of other GEP tests will need to consider factors such as patient group applicability, cost, and practicality of use in Ireland.

Conclusion:

Shelley O’Neill, who is the Deputy Director of HTA at HIQA, pointed out that GEP tests have the potential to identify individuals who might not require chemotherapy. This would be beneficial to both the patient and the healthcare system. We need to collect more data on the use of GEP tests in Ireland. This would lead to a more comprehensive evaluation of the potential applications of these tests in the future.

Reference url

Recent Posts

Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity

By João L. Carapinha

July 31, 2025

The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...
ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in Low-Income Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool. The update now includes access to long-acting injectable cabotegravir (CAB LA) for HIV treatment. This allows generic manufacturers to supply the therapy in 133 low- and middle-income countries (LMICs)....